Latest Market Outlook News

Sigma Healthcare has received Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in its strategic expansion. The scheme is set to become legally effective on February 4, 2025, with implementation expected by February 12.

OzAurum Resources has announced a significant new high-grade gold discovery at its Mulgabbie North Gold Project in Western Australia, revealing multiple shallow intercepts that could expand its existing resource base.

Astral Resources NL has initiated an off-market takeover offer for Maximus Resources Limited, proposing one Astral share for every two Maximus shares. The Maximus Board unanimously recommends acceptance, highlighting a significant premium and strategic consolidation benefits.

Strandline Resources reports a decline in mineral sands production and sales in the December 2024 quarter, impacted by lower ore grades and mechanical setbacks, while actively negotiating debt restructuring and advancing key infrastructure projects.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

European Metals Holdings Limited has clarified its recent Concept Study results for the Cinovec lithium project, retracting previous production targets while highlighting a potential increase in production capacity pending Definitive Feasibility Study confirmation.

Duxton Water Limited reports a $22 million increase in its water portfolio value for December 2024, driven by strategic acquisitions and rising allocation prices amid persistent dry weather in the Murray-Darling Basin.

Simble Solutions reports a robust Q4 FY24 with a 117% jump in customer receipts and a strategic $280k capital placement, underpinning its growth in energy and sustainability software.

Pure Foods Tasmania reports improved revenue and gross profit margin for 2Q25, driven by aggressive cost-cutting and operational efficiencies, while continuing negotiations to lift its ASX trading suspension.

Oldfields Holdings Limited reports a robust second quarter for FY2025, highlighting successful strategic realignment and improved financial performance despite ongoing transition costs.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.